共 50 条
- [1] Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wang, MichaelRossi, John M.Munoz, JavierGoy, AndreLocke, Frederick LundryReagan, Patrick MichaelJacobson, Caron A.Hill, Brian T.Holmes, HoustonJaglowski, Samantha MaryPeng, WeiminZheng, LianqingFang, XiangXue, AllenRao, Arati, VBot, Adrian
- [2] One year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/Refractory mantle cell lymphomaBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 42 - 43Wang, Michael L.Munoz, JavierGoy, AndreLocke, Frederick L.Jacobson, Caron A.Hill, Brian T.Timmerman, John M.Holmes, HoustonJaglowski, SamanthaFlinn, Ian W.McSweeney, Peter A.Miklos, David B.Pagel, John M.Kersten, Marie JoseMilpied, NoelFung, Henry C. H.Topp, Max S.Houot, RochBeitinjaneh, AmerPeng, WeiminZheng, LianqingRossi, John M.Murugappan, SwaminathanKloos, IoanaReagan, Patrick M.
- [3] One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell LymphomaBLOOD, 2020, 136Wang, MichaelMunoz, JavierGoy, Andre H.Locke, Frederick L.Jacobson, Caron A.Hill, Brian T.Timmerman, John M.Holmes, HoustonJaglowski, SamanthaFlinn, Ian W.McSweeney, Peter A.Miklos, David B.Pagel, John M.Kersten, Marie JoseMilpied, NoelFung, Henry C. H.Topp, Max S.Houot, RochBeitinjaneh, AmerPeng, WeiminZheng, LianqingRossi, John M.Murugappan, SwaminathanKloos, IoanaReagan, Patrick M.
- [5] Pharmacological profile and clinical outcomes of KTE-X19 by prior bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/refractory mantle cell lymphoma in the ZUMA-2 trialBRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 43 - 44Wang, MichaelRossi, John M.Munoz, JavierGoy, AndreLocke, Frederick L.Reagan, Patrick M.Jacobson, Caron A.Hill, Brian T.Holmes, HoustonJaglowski, SamanthaPeng, WeiminZheng, LianqingFang, XiangXue, AllenKloos, IoanaBot, Adrian
- [6] Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 TrialBLOOD, 2020, 136Wang, MichaelRossi, John M.Munoz, JavierGoy, Andre H.Locke, Frederick L.Reagan, Patrick M.Jacobson, Caron A.Hill, Brian T.Holmes, HoustonJaglowski, SamanthaPeng, WeiminZheng, LianqingFang, XiangXue, AllenKloos, IoanaBot, Adrian
- [7] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)BLOOD, 2022, 140 : 9320 - 9322Munoz, JavierReagan, Patrick M.Goy, Andre H.Miklos, David B.Zheng, DanFang, XiangShen, Rhine R.Siddiqi, RubinaKloos, IoanaKersten, Marie JoseWang, Michael
- [9] KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in patients with relapsed/refractory mantle cell lymphoma: results from phase 2 of ZUMA-2BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 28 - 29Wang, M.Munoz, J.Goy, A.Locke, F.Jacobson, C.Hill, B.Timmerman, J.Holmes, H.Jaglowski, S.Flinn, I.McSweeney, P.Miklos, D.Pagel, J.Kersten, M. J.
- [10] ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Wang, MichaelLocke, Frederick LundryMunoz, JavierGoy, AndreHolmes, Houston EcclestonSiddiqi, TanyaFlinn, IanMcSweeney, Peter A.Reagan, Patrick MichaelHill, Brian ThomasJacobson, Caron A.Rizzieri, David A.Heffner, Leonard T.Jaglowski, Samantha MaryMiklos, David BernardShaughnessy, PaulUnabia, SherryRossi, John M.Jiang, YizhouJain, Rajul K.